Surita Roux

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

Glenda Gray, Mary Allen, Zoe Moodie et al. · The Lancet Infectious Diseases · 2011 · 382 citations · Full text

Vaccination, Hvtn 503/Phambili, Human Retrovirus +9

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Dan H. Barouch, Sandra V. Kik, Gerrit Jan Weverling et al. · Vaccine · 2011 · 302 citations

Diagnostic Virology, Viral Diagnostics, International Seroepidemiology +5

Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework

K. Rivet Amico, Melissa Wallace, Linda‐Gail Bekker et al. · AIDS and Behavior · 2016 · 147 citations · Full text

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Glenda Gray, Zoe Moodie, Barbara Metch et al. · The Lancet Infectious Diseases · 2014 · 119 citations · Full text

Vaccination, Vaccine Development, Phase 2B +9

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial

Linda‐Gail Bekker, Surita Roux, Elaine Sebastien et al. · The Lancet HIV · 2017 · 115 citations · Full text

Contraception, Preventive Medicine, Treatment And Prevention +8